Acceleron to Webcast Second Quarter 2021 Financial Results on August 5, 2021
Acceleron Pharma announced a webcast and conference call on August 5, 2021, at 5:00 p.m. EDT to discuss its Q2 2021 financial results. The event will be accessible via the company's website. The company focuses on therapeutics for serious diseases, particularly pulmonary and hematologic conditions. Acceleron is advancing sotatercept for pulmonary hypertension, following positive Phase 2 results, and is set to initiate the CADENCE Phase 2 trial this year. REBLOZYL, in collaboration with Bristol Myers Squibb, targets anemia in specific blood disorders.
- Sotatercept shows promising results in Phase 2 for pulmonary hypertension.
- Expansion of sotatercept development into Group 2 PH.
- REBLOZYL is the first approved erythroid maturation agent in multiple regions.
- None.
Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Thursday, August 5, 2021 at 5:00 p.m. EDT to discuss its second quarter 2021 financial results.
The webcast will be accessible under "Events & Presentations" in the Investors & Media page of the Company’s website at www.acceleronpharma.com. To participate in the conference call, please dial 833-494-1483 (domestic) or 236-714-2620 (international) and reference conference ID #5736809.
An archived version of the webcast will be available for replay on the Company’s website for approximately one year.
About Acceleron
Acceleron is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Acceleron’s leadership in the understanding of TGF-beta superfamily biology and protein engineering generates innovative compounds that engage the body's ability to regulate cellular growth and repair.
Acceleron focuses its research, development, and commercialization efforts in pulmonary and hematologic diseases. In pulmonary, Acceleron is developing sotatercept for the treatment of pulmonary hypertension (PH). Following positive PULSAR Phase 2 results, Acceleron is executing on its Phase 3 development plan to support its long-term vision of establishing sotatercept as a backbone therapy for patients with pulmonary arterial hypertension (PAH) at all stages of the disease. Acceleron is also expanding the development of sotatercept into Group 2 PH, with the CADENCE Phase 2 trial expected to initiate this year. Acceleron has expanded its rare pulmonary disease pipeline and is investigating the potential of ACE-1334 in a Phase 1b/Phase 2 trial in systemic sclerosis-associated interstitial lung disease (SSc-ILD).
In hematology, REBLOZYL® (luspatercept-aamt) is the first and only erythroid maturation agent approved in the United States, Europe, and Canada for the treatment of anemia in certain blood disorders. REBLOZYL is part of a global collaboration partnership with Bristol Myers Squibb. The Companies co-promote REBLOZYL in the United States and are also developing luspatercept for the treatment of anemia in patient populations of myelodysplastic syndromes, beta-thalassemia, and myelofibrosis.
For more information, please visit www.acceleronpharma.com. Follow Acceleron on Social Media: @AcceleronPharma and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210726005087/en/
FAQ
What are the key highlights from Acceleron Pharma's Q2 2021 financial results?
When will Acceleron Pharma discuss its financial results?
What is sotatercept and its significance in Acceleron's pipeline?
What is Acceleron's partnership with Bristol Myers Squibb?
